Found: 19
Select item for more details and to access through your institution.
Partial MHC class II constructs inhibit MIF/ CD74 binding and downstream effects.
- Published in:
- European Journal of Immunology, 2013, v. 43, n. 5, p. 1309, doi. 10.1002/eji.201243162
- By:
- Publication type:
- Article
TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes.
- Published in:
- European Journal of Immunology, 2011, v. 41, n. 5, p. 1465, doi. 10.1002/eji.201041241
- By:
- Publication type:
- Article
RTL551 Treatment of EAE Reduces CD226 and T-bet+ CD4 T Cells in Periphery and Prevents Infiltration of T-bet+ IL-17, IFN-&ggr; Producing T Cells into CNS.
- Published in:
- PLoS ONE, 2011, v. 6, n. 7, p. 1, doi. 10.1371/journal.pone.0021868
- By:
- Publication type:
- Article
Decreased FOXP3 levels in multiple sclerosis patientsA.A.V. has a significant financial interest in The Immune Response Corporation, a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by the OHSU and VAMC Conflict of Interest Committees.
- Published in:
- Journal of Neuroscience Research, 2005, v. 81, n. 1, p. 45, doi. 10.1002/jnr.20522
- By:
- Publication type:
- Article
T‐cell hybridoma specific for myelin oligodendrocyte glycoprotein‐35–55 peptide produced from HLA‐DRB1*1501‐transgenic mice.
- Published in:
- Journal of Neuroscience Research, 2004, v. 77, n. 5, p. 670, doi. 10.1002/jnr.20201
- By:
- Publication type:
- Article
CD4 T-cell epitopes of human α B-crystallin.
- Published in:
- Journal of Neuroscience Research, 2004, v. 75, n. 4, p. 516, doi. 10.1002/jnr.20000
- By:
- Publication type:
- Article
Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.
- Published in:
- Metabolic Brain Disease, 2012, v. 27, n. 2, p. 143, doi. 10.1007/s11011-012-9289-7
- By:
- Publication type:
- Article
Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice.
- Published in:
- Metabolic Brain Disease, 2011, v. 26, n. 2, p. 123, doi. 10.1007/s11011-011-9241-2
- By:
- Publication type:
- Article
Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells.
- Published in:
- Stem Cells Translational Medicine, 2015, v. 4, n. 12, p. 1436, doi. 10.5966/sctm.2014-0225
- By:
- Publication type:
- Article
Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand.
- Published in:
- Journal of Neuroscience, 2009, v. 29, n. 12, p. 3816, doi. 10.1523/JNEUROSCI.5812-08.2009
- By:
- Publication type:
- Article
A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS.
- Published in:
- Journal of Neuroscience, 2007, v. 27, n. 46, p. 12531, doi. 10.1523/JNEUROSCI.3599-07.2007
- By:
- Publication type:
- Article
Characterization of human platelet binding of recombinant T cell receptor ligand.
- Published in:
- Journal of Neuroinflammation, 2010, v. 7, p. 75, doi. 10.1186/1742-2094-7-75
- By:
- Publication type:
- Article
A Promising Therapeutic Approach for Treatment of Posterior Uveitis: Recombinant T Cell Receptor Ligand Protects Lewis Rats from Acute and Recurrent Experimental Autoimmune Uveitis.
- Published in:
- Ophthalmic Research, 2010, v. 44, n. 1, p. 24, doi. 10.1159/000281815
- By:
- Publication type:
- Article
Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG.
- Published in:
- Journal of NeuroImmune Pharmacology, 2010, v. 5, n. 2, p. 231, doi. 10.1007/s11481-009-9175-1
- By:
- Publication type:
- Article
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
- Published in:
- Autoimmune Diseases (2090-0422), 2012, p. 1, doi. 10.1155/2012/954739
- By:
- Publication type:
- Article
Antigen-Specific Therapy Promotes Repair of Myelin and Axonal Damage in Established EAE.
- Published in:
- Journal of Neurochemistry, 2006, v. 98, n. 6, p. 1817, doi. 10.1111/j.1471-4159.2006.04081.x
- By:
- Publication type:
- Article
Self-presentation of beryllium by BAL CD4.
- Published in:
- European Journal of Immunology, 2006, v. 36, n. 4, p. 930, doi. 10.1002/eji.200526075
- By:
- Publication type:
- Article
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
- Published in:
- European Journal of Immunology, 2004, v. 34, n. 5, p. 1251, doi. 10.1002/eji.200324354
- By:
- Publication type:
- Article